Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Large Is the Nephrology Drugs Market Expected to Be in 2029?

In recent times, the nephrology drugs market has been experiencing a consistent growth. The market size, which was at $16.88 billion in 2024, is predicted to increase to $17.69 billion in 2025, representing a compound annual growth rate (CAGR) of 4.8%. The growth during the historical period can be linked to the rising occurrence of chronic kidney diseases (CKD), progress in drug development, higher levels of awareness and diagnosis, government interventions, and health policies, along with a growing number of diabetes incidents.

In the coming years, the nephrology drugs market is anticipated to experience robust growth, increasing to “$22.61 billion by 2029 with a compound annual growth rate (CAGR) of 6.3%. The predicted expansion during this forecast period can be linked to the emergence of new therapies and drug developments, precision and personalized treatment methods, a rise in healthcare spending, the utilization of telehealth and remote patient monitoring, as well as global health endeavors. Key trends expected during this period include strategic alliances and partnerships, innovations in dialysis technology, progress in treatment methodologies, an intensified focus on early detection and intervention, and the adoption of technology in nephrology management.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10076&type=smp

What Are The Contributors To Demand In The Nephrology Drugs Market?

The increasing incidents of chronic kidney disease (CKD) are set to fuel the advancement of the nephrology drugs market, as CKD signifies kidney damage preventing efficient blood filtration. This damage, which tends to develop over a long duration, could lead to wastage accumulation in the body. Nephrology drugs play a key role in CKD treatment to improve kidney functionality and retard the disease, thus keeping it from inflicting further damage. Such factors enhance the appeal of the nephrology drugs market. For instance, the Centers for Disease Control and Prevention (CDC), a health protection agency based in the US, reported in July 2022 that over 37 million people in the US were afflicted with chronic kidney disease, especially prevalent in those aged 65 years or more (38 percent). Similarly, the Kidney Foundation of Canada, a non-profit organization, stated that 4 million Canadians suffer from kidney diseases, with diabetic patients constituting about 35 percent of the cases leading to kidney failure. It’s anticipated that these statistics will increase in the future, which further highlights the potential of chronic kidney disease as a key growth driver for the nephrology drug market.

The nephrology drugs market covered in this report is segmented –

1) By Drugs: Antihypertensive Agents, Erythropoiesis-Stimulating Agents, Diuretics, ACE Inhibitors, Antidiabetic Agents, Other Drugs

2) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Antihypertensive Agents: Calcium Channel Blockers, Beta-Blockers, Angiotensin II Receptor Blockers (ARBs)

2) By Erythropoiesis-Stimulating Agents: Epoetin Alfa, Darbepoetin Alfa

3) By Diuretics: Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics

4) By ACE Inhibitors: Lisinopril, Enalapril

5) By Antidiabetic Agents: Metformin, Insulin

6) By Other Drugs: Phosphate Binders, Vitamin D Analogues, Renin Inhibitors

What Notable Trends Are Shaping The Direction Of The Nephrology Drugs Market?

In the nephrology drug market, the key trend that is rapidly gaining traction is product innovation. To maintain their significant market positions, major companies within this industry are developing new products and drugs. Take for example, in March 2022, India’s pharmaceutical firm Zydus Lifesciences Limited released Oxemia (desidustat) for the treatment of chronic kidney disease (CKD). This drug, an orally administered small-molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, provides a convenient treatment option for anemia and has been approved by India’s Drug Controller General. In phase III clinical trials, it showed promising safety profiles, downregulation of hepcidin, improved iron mobilization and a decrease in LDL-C for patients with chronic kidney disease. Furthermore, its affordable price and ability to improve the patient’s quality of life can potentially alleviate the disease’s impact.

Who Are The Top-Ranked Companies In The Nephrology Drugs Market Today?

Major companies operating in the nephrology drugs market include AstraZeneca plc, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., F. Hoffmann-La Roche AG, FibroGen Inc., Johnson And Johnson, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S, Novartis AG, Baxter International Inc., Bristol Myers Squibb Company, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, OPKO Health Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vifor Pharma Group, Bayer AG, Amicus Therapeutics, Chugai Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., Endo Pharmaceuticals plc

https://www.thebusinessresearchcompany.com/report/nephrology-drugs-global-market-report

How Is Nephrology Drugs Market Adoption Varying Across Different Regions And Sectors?

North America was the largest region in the nephrology drug market in 2024.Europe will be the second-largest growing region in the nephrology drug market in 2024. The regions covered in the nephrology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10076&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model